← Eichor
Study identifier: NCT06709872 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Prospective Multicenter Diagnostic Biomarker Study to Discriminate Borderline From Stage I Invasive Ovarian Cancer

Condition: Stage I Ovarian Cancer · Borderline Ovarian Tumors  ·  Sponsor: KU Leuven

PhaseN/A
Planned participants400
Who can joinFemale, 18 Years to no upper limit
Healthy volunteersNo

About this study

The study aims to improve the diagnosis of ovarian cancer by distinguishing between borderline ovarian tumors (BOT) and stage I invasive ovarian cancer. Other than the traditional diagnostic biomarker CA125, the previous study TRANS-IOTA (translational-international ovarian tumor analysis; S51375/S59207), conducted by similar investigators, pointed at biomarkers like HE4, CA72.4, CA15.3, and CCL11, as potential markers to discriminate BOT from stage I cancer. BIOC is the follow-up study, which will include four additional promising biomarkers to expand the panel to nine. The investigators aim to confirm whether a subpanel of these nine biomarkers has diagnostic value. Such a biomarker signature would enhance the accuracy of distinguishing between BOT and stage I invasive ovarian cancer before surgery, leading to more precise treatment and improved patient outcomes.

This description comes directly from the study's public registry record.

Talk to the study team

An Coosemans  ·  +32 16 37 77 88  ·  an.coosemans@kuleuven.be

Kainat Jamil  ·  +32 16 37 39 88  ·  kainat.jamil@kuleuven.be

Always discuss trial participation with your own doctor first.

Locations (4)

UZ LeuvenLeuven, Flemish Brabant, BelgiumRecruiting
General Faculty Hospital of the Charles UniversityPrague, CzechiaRecruiting
Istituto Nazionale dei TumoreMilan, ItalyNot Yet Recruiting
Università Cattolica del Sacro CuoreRome, ItalyNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06709872